The physiologic role and therapeutic potential of the Mpl-ligand in thrombopoiesis

Stem Cells
P Hunt

Abstract

The constant and appropriate production of megakaryocytes, and subsequently platelets, is critical for maintenance of hemostasis. Inadequate megakaryopoiesis and/or thrombopoiesis can lead to serious bleeding disorders. The humoral factors regulating these processes have been the subject of study for several decades. Although many cytokines have been shown to influence megakaryocyte development and platelet production, none appeared to do so in a lineage-dominant fashion analogous to the situation with erythrocyte and neutrophil production. More recently, a ligand for the hematopoietic cytokine receptor encoded by the c-mpl gene (Mpl ligand) has been shown to have profound effects on megakaryocyte growth and development. These effects appear to include the expansion of megakaryocyte progenitors (i.e. megakaryocyte-colony stimulating activity), and induction of megakaryocyte maturation to the point of platelet production (i.e. thrombopoietin). Administration of recombinant Mpl-ligand to rodents or primates treated with myelosuppressive agents abrogates or alleviates the severity and the duration of the resultant thrombocytopenias. The in vitro and in vivo data to date indicate that this new cytokine holds tremendous promise as a...Continue Reading

References

Oct 1, 1979·Neuroscience and Behavioral Physiology·V V PetukhovO V Godukhin
Sep 1, 1979·Cell and Tissue Kinetics·H E WichmannR Gross
Jan 1, 1990·Progress in Growth Factor Research·N Williams
Jul 1, 1990·International Journal of Cell Cloning·C W JacksonT P McDonald
Jan 1, 1990·International Journal of Cell Cloning·K OgataM J Murphy
Sep 1, 1989·Clinical Pharmacology and Therapeutics·E M Mazur, J L Cohen
Jul 27, 1972·The New England Journal of Medicine·L A Harker, S J Slichter
Mar 1, 1967·British Journal of Haematology·G De Gabriele, D G Penington
Sep 1, 1981·The Journal of Clinical Investigation·E M MazurE Bruno
Mar 10, 1995·The Journal of Biological Chemistry·J G DrachmanK Kaushansky
Jun 9, 1995·Gene·K OgamiH Miyazaki
Dec 20, 1994·Proceedings of the National Academy of Sciences of the United States of America·D C FosterA F Ching
Nov 8, 1994·Proceedings of the National Academy of Sciences of the United States of America·D J KuterR D Rosenberg
Sep 2, 1994·Science·A L GurneyM W Moore
Jun 16, 1994·Nature·F WendlingW Vainchenker
Jan 1, 1994·Virchows Archiv : an International Journal of Pathology·D RohdeR Fischer
Jul 1, 1995·Journal of Biochemistry·T KatoE Maeda
Oct 1, 1961·Proceedings of the Society for Experimental Biology and Medicine·B SPECTOR
Nov 1, 1961·Proceedings of the Society for Experimental Biology and Medicine·T T ODELLT C DETWILER

❮ Previous
Next ❯

Citations

Dec 1, 1995·Current Opinion in Biotechnology·P Hunt, M Foote
Aug 8, 1998·The International Journal of Biochemistry & Cell Biology·J E Rasko, C G Begley
May 1, 2007·Regenerative Medicine·S RocheS Lehmann
Jul 1, 1998·International Reviews of Immunology·W S Alexander
Oct 25, 2011·Expert Opinion on Therapeutic Patents·Amanda B SmithDavid J Craik
Apr 6, 2006·The American Psychologist·Roger Walsh, Shauna L Shapiro
Sep 25, 1999·Growth Factors·W S Alexander

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.